Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomes.
Saito S, Takahashi H, Yata Y, Takamizawa S, Hara S, Miyajima K, Iwatani K, Yasue K, Nishikawa H, Yamamoto T, Koide H, Sadakane I, Atsuta M, Mori K, Imai Y, Kayano S, Murakami M, Tashiro K, Tsuzuki S, Yamada H, Miki J, Urabe F, Kimura T, On Behalf Of Jikei-Scrum Collaborative Group. Saito S, et al. Among authors: yata y. Jpn J Clin Oncol. 2024 Nov 2;54(11):1201-1207. doi: 10.1093/jjco/hyae081. Jpn J Clin Oncol. 2024. PMID: 38920339
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study.
Takahashi K, Urabe F, Suhara Y, Nakano J, Yoshihara K, Goto Y, Sadakane I, Koike Y, Yata Y, Suzuki H, Kurawaki S, Miyajima K, Iwatani K, Imai Y, Sakanaka K, Nakazono M, Kurauchi T, Kayano S, Onuma H, Aikawa K, Yanagisawa T, Tashiro K, Tsuzuki S, Koike Y, Furuta A, Miki J, Kimura T. Takahashi K, et al. Among authors: yata y. Jpn J Clin Oncol. 2023 Dec 7;53(12):1208-1214. doi: 10.1093/jjco/hyad118. Jpn J Clin Oncol. 2023. PMID: 37647644
Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.
Kagawa H, Urabe F, Kiuchi Y, Katsumi K, Yamaguchi R, Suhara Y, Yoshihara K, Goto Y, Sadakane I, Yata Y, Saito S, Kurawaki S, Ajisaka S, Miyajima K, Takahashi K, Iwatani K, Imai Y, Sakanaka K, Nakazono M, Kurauchi T, Kayano S, Onuma H, Aikawa K, Yanagisawa T, Tashiro K, Tsuzuki S, Furuta A, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Kagawa H, et al. Among authors: yata y. Int J Clin Oncol. 2024 Jan;29(1):55-63. doi: 10.1007/s10147-023-02424-9. Epub 2023 Oct 21. Int J Clin Oncol. 2024. PMID: 37863996
Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective study.
Uchida N, Urabe F, Suhara Y, Goto Y, Yoshihara K, Sadakane I, Yata Y, Kurawaki S, Miyajima K, Ishikawa M, Takahashi K, Iwatani K, Imai Y, Sakanaka K, Nakazono M, Hisakane A, Kurauchi T, Kayano S, Onuma H, Mori K, Aikawa K, Yanagisawa T, Tashiro K, Tsuzuki S, Miki J, Furuta A, Sato S, Takahashi H, Kimura T. Uchida N, et al. Among authors: yata y. Transl Androl Urol. 2024 Mar 31;13(3):414-422. doi: 10.21037/tau-23-561. Epub 2024 Mar 6. Transl Androl Urol. 2024. PMID: 38590954 Free PMC article.
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
Hara S, Mori K, Fukuokaya W, Tomomasa N, Oguchi T, Takahashi Y, Saito S, Katami J, Sano T, Kadena S, Hashimoto M, Yata Y, Nishi E, Suhara Y, Takamizawa S, Kurawaki S, Suzuki H, Miyajima K, Iwatani K, Urabe F, Ito K, Yanagisawa T, Tsuzuki S, Shimomura T, Kimura T. Hara S, et al. Among authors: yata y. Int J Clin Oncol. 2024 Aug;29(8):1191-1197. doi: 10.1007/s10147-024-02548-6. Epub 2024 May 20. Int J Clin Oncol. 2024. PMID: 38769191
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: yata y. Prostate. 2023 May;83(6):563-571. doi: 10.1002/pros.24488. Epub 2023 Jan 20. Prostate. 2023. PMID: 36661102
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. Among authors: yata y. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Saruta M, Takahara K, Fujita K, Minami T, Adachi T, Hirasawa Y, Hashimoto T, Ohno Y, Uemura H, Shiroki R, Azuma H, Kimura T. Fukuokaya W, et al. Among authors: yata y. Int J Urol. 2024 Apr;31(4):342-347. doi: 10.1111/iju.15368. Epub 2023 Dec 19. Int J Urol. 2024. PMID: 38113343
121 results